ABSTRACT
SETTING: Tuberculosis (TB) incidence is declining overall in France, but not in Paris where some areas remain relative hot spots for TB.OBJECTIVES: To obtain a better knowledge of local TB epidemiology in order to facilitate control measures.DESIGN: Analysis of demographic data of TB patients diagnosed at the Bichat-Claude Bernard Hospital from 2007 to 2016, with spoligotyping of Mycobacterium tuberculosis complex isolates.RESULTS: During the study period, 1096 TB patients were analysed. The incidence of TB diagnosis was stable, averaging 115 patients per year, predominantly males (71%), foreign-born (81%), with pulmonary TB (77%) and negative HIV serology (88%). The mean age of foreign-born TB patients decreased over the study period, most significantly in recent arrivals in France, whose average age decreased by two years (P = 0.001). The time period between arrival in France and being diagnosed with active TB decreased annually significantly by 0.75 years (P = 0.02). The proportion of L4.6.2/Cameroon and L2/Beijing sub-lineages increased annually by 0.7% (P < 0.05). Multi-drug resistant strains, representing 4% of all strains, increased annually by 0.75% (P = 0.03)CONCLUSION: The number of TB patients remained high in northern Paris and the surrounding suburbs, suggesting the need for increased control measures.
Subject(s)
Mycobacterium tuberculosis , Tuberculosis, Multidrug-Resistant , Tuberculosis , Beijing , Cameroon , Child, Preschool , France/epidemiology , Humans , Male , Paris/epidemiology , Tuberculosis/diagnosis , Tuberculosis/epidemiologyABSTRACT
BACKGROUND: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (TB) constitute a major public health concern. OBJECTIVE: To determine the timing of pncA mutations that confer pyrazinamide (PZA) resistance in relation to mutations conferring resistance to isoniazid (INH) and rifampicin (RMP). DESIGN: Isolates from two major urban centres--Paris (101 strains) and Shanghai (171 strains)--were investigated for the association of pncA mutations with resistance to drugs other than PZA. RESULTS: The proportion of pncA mutations found in INH-monoresistant strains was not increased. CONCLUSION: pncA mutations associated with PZA resistance were found almost exclusively in MDR-TB strains, underlining the importance of determining PZA resistance when treating MDR- or XDR-TB.
Subject(s)
Antitubercular Agents/therapeutic use , Drug Resistance, Multiple, Bacterial , Fluoroquinolones/therapeutic use , Mycobacterium tuberculosis/drug effects , Pyrazinamide/therapeutic use , Rifampin/therapeutic use , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Multidrug-Resistant/microbiology , Amidohydrolases/genetics , China/epidemiology , DNA Mutational Analysis , DNA, Bacterial/genetics , Drug Resistance, Multiple, Bacterial/genetics , Extensively Drug-Resistant Tuberculosis/diagnosis , Extensively Drug-Resistant Tuberculosis/drug therapy , Extensively Drug-Resistant Tuberculosis/epidemiology , Extensively Drug-Resistant Tuberculosis/microbiology , Gene Frequency , Genotype , Humans , Microbial Sensitivity Tests , Mutation , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/isolation & purification , Paris/epidemiology , Phenotype , Tuberculosis, Multidrug-Resistant/diagnosis , Tuberculosis, Multidrug-Resistant/epidemiologySubject(s)
Toxicology , Toxicology , Biodiversity , Poisons , Poisoning , Toxins, Biological , ToxicologyABSTRACT
In a study performed in Cambodia, a higher number of tuberculosis (TB) strains with mutations in the pncA gene associated with pyrazinamide resistance (PZA-R) was found in fluoroquinolone-resistant (FQ-R) multidrug-resistant (MDR) strains (93%), compared with 47% in MDR and 3% in non-MDR strains. This emphasises the need for easy and rapid tests for identification of PZA-R for efficient treatment of MDR-TB.
Subject(s)
Amidohydrolases/genetics , DNA, Bacterial/genetics , Fluoroquinolones/therapeutic use , Mutation , Mycobacterium tuberculosis/genetics , Pyrazinamide/therapeutic use , Tuberculosis, Multidrug-Resistant/drug therapy , Antitubercular Agents/therapeutic use , Cambodia/epidemiology , Genotype , Humans , Incidence , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/isolation & purification , Retrospective Studies , Tuberculosis, Multidrug-Resistant/epidemiology , Tuberculosis, Multidrug-Resistant/microbiologyABSTRACT
Multidrug-resistant (MDR) strains were identified in 40% of 54 strains from patients presenting with tuberculosis (TB) treatment failure or relapse in Bangui, Central African Republic. Results obtained with the MTBDRplus line-probe assay or rpoB sequencing were 86% concordant with rifampicin (RMP) resistant phenotypes, while the amplification refractory mutation system test was 71% concordant. No mutation was found in RMP-susceptible strains. MTBDRplus and sequencing were concordant with the detection of the S315T mutation in katG in 95% of MDR strains. Sequencing of pncA suggested pyrazinamide resistance in 50% of MDR strains. Knowledge of these resistances should help to implement treatment in low-income countries.
Subject(s)
Antitubercular Agents/therapeutic use , DNA, Bacterial/genetics , Drug Resistance, Multiple, Bacterial/genetics , Mutation , Mycobacterium tuberculosis/isolation & purification , Tuberculosis, Multidrug-Resistant/microbiology , Central African Republic/epidemiology , Humans , Incidence , Mycobacterium tuberculosis/genetics , Polymerase Chain Reaction , Prevalence , Recurrence , Retrospective Studies , Treatment Failure , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Multidrug-Resistant/epidemiologyABSTRACT
To ascertain the in vivo role of mycobacterial lipids phthiocerol dimycocerosates (PDIM) in experimental murine tuberculosis (Tb), airways infection was used to compare the parental virulent clinical isolate MT103 with its mutant fadD26, lacking PDIM. Lungs were assessed as the Tb-target organ and mediastinal lymph nodes as the corresponding lymphoid tissue, in order to quantify: the major T-cell subsets (CD4+/CD8+/gammadelta+) and their activation kinetics, bacillary burden, and in vivo cytotoxicity against inoculated target cells loaded with mycobacterial Ags. After 4 weeks, infection augmented total and activated CD4+ and CD8+ T cells in lungs and nodes mainly with MT103, while gammadelta+ T cells increased earlier in nodes. MT103 bacillary burden was bigger and appeared earlier than the mutant fadD26, especially in the lung than in mediastinal nodes. At day 14 of MT103 infection, there was no cytotoxicity in lungs and nodes; while with fadD26 there was some in the nodes. At day 21 of MT103 infection, important cytotoxicity was detected only in lungs; while with fadD26 both tissues showed important activity. Interestingly, unlike the infection with fadD26, cytotoxicity under MT103 fell considerably in the target organ (lung) from days 21 to 60, the advanced phase. Although upon airways infection both mycobacteria behaved similarly regarding T cell (CD4/CD8/gammadelta) stimulation kinetics; they differed in the magnitude of these responses, in the bacterial load within tissues, and to trigger in vivo cytotoxicity in lungs and regional lymph nodes. This highlights the relevance of certain mycobacterial lipids to modify crucial effector branches of immunity.
Subject(s)
Cytotoxicity, Immunologic , Lipids/physiology , Lung/immunology , Lymph Nodes/immunology , T-Lymphocytes/immunology , Tuberculosis/immunology , Animals , Hypersensitivity, Delayed , Lymphocyte Activation , Male , Mice , Mice, Inbred BALB C , Tuberculosis/microbiologyABSTRACT
Safety is one of the main concerns for attenuated live vaccine candidates. Here we extend the stability and attenuation studies of the promising tuberculosis vaccine candidate based on Mycobacterium tuberculosis phoP mutant strain, SO2. Stability of the phoP mutation was tested after sub-culturing SO2 strain for 6 months in laboratory media and also after 3 months of infection in SCID mice. Results showed no reversion of the phoP mutation either in vitro or in vivo. In addition, SO2 was fully sensitive to four major first-line antituberculous drugs against tuberculosis. Safety and toxicity studies were performed in guinea pigs. Animals were infected with a quantity of SO2 equivalent to 50 vaccination doses (2.5x10(6) CFUs) and weight was monitored for 6 months. All animals survived and no histological lesions were found, showing full attenuation of SO2. Studies in a post-exposure model of guinea pigs and mice, previously infected with M. tuberculosis, were performed and no toxicity effects were found after inoculation of SO2. All these results together confirm that SO2 has a secure safety profile that encourages its use in clinical trials.
Subject(s)
Bacterial Proteins/genetics , Tuberculosis Vaccines/adverse effects , Animals , Female , Guinea Pigs , Mice , Mice, Inbred C57BL , Mutation , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/pathogenicity , Vaccines, Attenuated/adverse effectsABSTRACT
The Mycobacterium tuberculosis phoP mutant strain SO2 has been shown previously to be more attenuated than Mycobacterium bovis bacillus Calmette-Guérin (BCG) and confers protective immunity against tuberculosis in mice and guinea pig models. In this study we have investigated the survival and immunological responses of Balb/c mice infected with the M. tuberculosis SO2 strain. All Balb/C mice survived intratracheal infection with M. tuberculosis SO2 strain under conditions where all the mice infected with the parental M. tuberculosis MT103 had died after 9 weeks. Infection of Balb/c mice with M. tuberculosis SO2 was associated with comparatively lower levels of interferon (IFN)-gamma, interleukin (IL)-4 and tumour necrosis factor (TNF)-alpha and higher levels of inducible nitric oxide synthase (iNOS) during the late stage of infection, when compared with M. tuberculosis MT103 infection. The delayed-type hypersensitivity (DTH) response against M. tuberculosis culture filtrates was similar in mice infected with either the M. tuberculosis phoP SO2 strain or M. tuberculosis MT103. The protective efficacy of M. tuberculosis SO2 was compared with M. bovis BCG when delivered subcutaneously to groups of Balb/C mice. Following intratracheal challenge with M. tuberculosis H37Rv, protection was generated by 60 days post-challenge in mice vaccinated with either vaccine. At day 120 post-challenge the levels of protection were still significantly greater when compared with the non-vaccinated control group. The levels of protection conferred by vaccination with M. tuberculosis SO2 or with M. bovis BCG were similar, as measured by granuloma coalescence and pneumonia in addition to growth reduction of M. tuberculosis H37Rv.
Subject(s)
Mycobacterium tuberculosis/immunology , Tuberculosis Vaccines/immunology , Tuberculosis, Pulmonary/prevention & control , Animals , BCG Vaccine/immunology , Cytokines/biosynthesis , DNA, Bacterial/analysis , Lung/immunology , Lung/microbiology , Mice , Mice, Inbred BALB C , Mycobacterium tuberculosis/classification , Mycobacterium tuberculosis/isolation & purification , Polymerase Chain Reaction/methods , Species Specificity , Tuberculosis, Pulmonary/immunology , Tuberculosis, Pulmonary/pathology , Vaccination , Vaccines, Attenuated/immunologyABSTRACT
Babesia bovis is the causative agent of babesiosis, a tick-borne disease that is a major cause of loss to livestock production in Latin America. Vaccination against Babesia species represents a major challenge against cattle morbidity and mortality in enzootic areas. The aim of this study was to evaluate the capacity of Bacille Calmette-Guerin (BCG) to deliver the rhoptry associated protein (RAP-1) antigen of B. bovis and to stimulate specific cellular and humoral immune responses in mice. Two of five mycobacterial expression vectors efficiently expressed the antigen. These constructs were subsequently studied in vivo following three immunization protocols. The construct with the greatest in vivo stability proved to be the one that induced the strongest immune responses. Our data support the hypothesis that specific T lymphocyte priming by rBCG can be employed as a component of a combined vaccine strategy to induce long-lasting humoral and cellular immune responsiveness towards B. bovis and encourage further work on the application of rBCG to the development of Babesia vaccines.
Subject(s)
Babesia bovis/genetics , Bacterial Vaccines/genetics , Gene Transfer Techniques , Mycobacterium bovis/genetics , Protozoan Proteins/biosynthesis , Animals , Babesia bovis/immunology , Bacterial Vaccines/immunology , Female , Mice , Mice, Inbred BALB C , Mycobacterium bovis/immunology , Protozoan Proteins/genetics , Protozoan Proteins/immunology , Vaccines, Combined/genetics , Vaccines, Combined/immunologyABSTRACT
The control of mycobacterial infections is dependent on the finely tuned synergism between the innate and adaptive immune responses. The macrophage is the major host cell for Mycobacterium tuberculosis and the degree of virulence of mycobacteria may influence the initial macrophage response to infection. The cell wall molecule, phthiocerol dimycocerosate (DIM), is an important virulence factor that influences the early growth of M. tuberculosis in the lungs. To explore the basis for this effect we have compared the early gene response of human THP-1 macrophages to infection with virulent M. tuberculosis and the DIM-deficient DeltafadD26 M. tuberculosis strain using microarrays. Detailed analysis revealed a common core of macrophage genes, which were rapidly induced following infection with both strains, and deficiency of DIM had no significant effect on this initial macrophage transcriptional responses. In addition to chemokines and pro-inflammatory cytokines, the early response genes included components of the Toll-like receptor signalling, antigen presentation and apoptotic pathways, interferon response genes, cell surface receptors and their ligands, including TNF-related apoptosis inducing ligand (TRAIL) and CD40, and other novel genes. Therefore, although fadD26 deficiency is responsible for the early attenuation of the growth of M. tuberculosis in vivo, this effect is not associated with differences in the initial macrophage transcriptional response.
Subject(s)
Lipids/deficiency , Macrophages/immunology , Macrophages/physiology , Mycobacterium tuberculosis/immunology , Animals , Antigens, Bacterial/immunology , Cell Line , Female , Flow Cytometry/methods , Humans , Kinetics , Macrophages/microbiology , Mice , Mice, Inbred C57BL , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/pathogenicity , Oligonucleotide Array Sequence Analysis , Reverse Transcriptase Polymerase Chain Reaction/methods , Transcriptional Activation , Virulence Factors/immunologyABSTRACT
Mycobacterium tuberculosis and Mycobacterium smegmatis MutT1, MutT2, MutT3, and Rv3908 (MutT4) enzymes were screened for an antimutator role. Results indicate that both MutT1, in M. tuberculosis and M. smegmatis, and MutT4, in M. smegmatis, have that role. Furthermore, an 8-oxo-guanosine triphosphatase function for MutT1 and MutT2 is suggested.
Subject(s)
Mycobacterium smegmatis/enzymology , Mycobacterium tuberculosis/enzymology , Pyrophosphatases/genetics , Pyrophosphatases/physiology , Gene Deletion , Genes, Bacterial , Guanosine Triphosphate/analogs & derivatives , Guanosine Triphosphate/metabolism , Mutagenesis, Insertional , Mutation , Mycobacterium smegmatis/genetics , Mycobacterium smegmatis/physiology , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/physiology , Nucleotides/metabolism , Pyrophosphatases/isolation & purification , Nudix HydrolasesABSTRACT
Given the variable protective efficacy generated by Mycobacterium bovis BCG (Bacillus Calmette-Guérin), there is a concerted effort worldwide to develop better vaccines that could be used to reduce the burden of tuberculosis. Rational attenuated mutants of Mycobacterium tuberculosis are vaccine candidates that offer some potential in this area. In this paper, we will discuss the molecular methods used to generate mutant mycobacteria, as well as the results obtained with some of these strains, in terms of attenuation, immunogenicity and level of protection, when compared with the conventional BCG vaccine in diverse animal models. Tuberculosis vaccine candidates based on safe and live mycobacterial mutants could be promising candidates.
Subject(s)
Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/immunology , Tuberculosis Vaccines/immunology , Tuberculosis/prevention & control , Animals , BCG Vaccine , Disease Models, Animal , Mutagenesis , Tuberculosis/immunology , Vaccines, Attenuated/immunologyABSTRACT
Every 10 seconds, one person in the world dies of tuberculosis (TB). It is estimated that one third of the world's population is latently infected with Mycobacterium tuberculosis. The proportion of multidrug-resistant strains of M. tuberculosis is increasing at an alarming rate in some parts of the world linked in part with the human immunodeficiency virus epidemic. For these reasons, TB remains a major public health problem, both in less-developed countries and in many industrialized countries, with 8-10 million new cases and 2 million deaths yearly in the world. Clinical, radiological and histological signs are not specific for tuberculosis or for other mycobacterial infections and allow only a presumptive diagnosis. In the same way, the tuberculin skin test is useful if the reaction is strong or phlyctenular because this test depends on various factors as previous BCG vaccination, contact or primary infection and host immune responses. The diagnosis of mycobacterial infection is proved only when bacilli are present in biological samples. Nevertheless, only 50% of cases in adults and 30% in infants have a positive bacteriological result. It seems necessary to develop new methods for a rapid and efficient diagnosis to optimize the therapy and the control of the epidemic. Laboratory testing in the mycobacterium field is experiencing more changes today than ever before. Determining what assays will be most useful to the clinician is a challenge, and acceptance of the new technology is under discussion. Progress in future will be linked probably to the progress of the genomic area. However the incidence rate is higher in less-developed countries, it is also important to develop now techniques possible to use in these countries. This review focuses on the current state-of-the-art resources useful for accurate and rapid laboratory diagnosis of mycobacterial infections.
Subject(s)
Bacteriological Techniques , Mycobacterium Infections/diagnosis , Bacteriological Techniques/methods , Base Sequence/genetics , Humans , Mycobacterium Infections/genetics , Mycobacterium tuberculosis/isolation & purification , Nucleic Acid Amplification Techniques , Polymerase Chain Reaction/methods , Tuberculosis/diagnosisABSTRACT
The Mycobacterium tuberculosis fadD26 mutant has impaired synthesis of phthiocerol dimycocerosates (DIM) and is attenuated in BALB/c mice. Survival analysis following direct intratracheal infection confirmed the attenuation: 60% survival at 4 months post-infection versus 100% mortality at 9 weeks post-infection with the wild-type strain. The fadD26 mutant induced less pneumonia and larger DTH reactions. It induced lower but progressive production of interferon (IFN)-gamma, interleukin (IL)-4 and tumour necrosis factor (TNF)-alpha. Used as a subcutaneous vaccine 60 days before intratracheal challenge with a hypervirulent strain of M. tuberculosis (Beijing code 9501000), the mutant induced a higher level of protection than did Bacille Calmette-Guérin (BCG). Seventy per cent of the mice vaccinated with the fadD26 mutant survived at 16 weeks after challenge compared to 30% of those vaccinated with BCG. Similarly, there was less tissue damage (pneumonia) and lower colony-forming units (CFU) in the mice vaccinated with the fadD26 mutant compared to the findings in mice vaccinated with BCG. These data suggest that DIM synthesis is important for the pathogenicity of M. tuberculosis, and that inactivation of DIM synthesis can increase the immunogenicity of live vaccines, and increase their ability to protect against tuberculosis.
Subject(s)
Mutation , Mycobacterium tuberculosis/genetics , Tuberculosis, Pulmonary/immunology , Animals , BCG Vaccine , Colony Count, Microbial , Cytokines/biosynthesis , Disease Models, Animal , Disease Progression , Hypersensitivity, Delayed/immunology , Male , Mice , Mice, Inbred BALB C , Mycobacterium tuberculosis/immunology , Mycobacterium tuberculosis/pathogenicity , Survival Analysis , Tuberculosis Vaccines , Tuberculosis, Pulmonary/microbiology , Tuberculosis, Pulmonary/pathology , Tuberculosis, Pulmonary/prevention & control , VirulenceSubject(s)
Toxicology , Toxicology , Poisons , Poisoning , Toxins, Biological , Toxicology , Allergy and Immunology , Cell Biology , GeneticsABSTRACT
Equine herpesviruses type 1 and 4 (EHV-1 and EHV-4) are ubiquitous in the equine population. One of their main properties is their ability to establish life-long latent infections in their hosts even in those with natural or vaccine-induced immunity. However, effect of vaccination status on prevalence and tissue tropism was not established. In this study, EHV-1 and EHV-4 were detected by polymerase chain reaction and by classical virus isolation from neural, epithelial and lymphoid tissues collected from unvaccinated (33) or vaccinated (23) horses. The percentage of EHV-1- and EHV-4-positive horses between vaccinates and unvaccinates was similar. Both viruses were detected in all tissues of both groups; in particular, lymph nodes draining the respiratory tract, nasal epithelium and nervous ganglia [i.e. trigeminal ganglia (TG)], which represent the main positive sites for EHV-1 and EHV-4. In vaccinated animals, the nervous ganglia (i.e. TG) were less frequently positive than in unvaccinated animals. Detection of positive TG was strongly correlated to the presence of EHV-1 in nasal epithelium.
Subject(s)
Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/immunology , Herpesvirus 4, Equid/immunology , Horse Diseases/epidemiology , Horse Diseases/prevention & control , Viral Vaccines , Animals , Autopsy , DNA Primers , DNA, Viral/genetics , France/epidemiology , Herpesviridae Infections/epidemiology , Herpesviridae Infections/prevention & control , Herpesvirus 1, Equid/genetics , Herpesvirus 4, Equid/genetics , Horse Diseases/virology , Horses , Polymerase Chain Reaction/veterinaryABSTRACT
Bivalent recombinant strains of Mycobacterium bovis BCG (rBCG) expressing the early regulatory nef and the structural gag(p26) genes from the simian immunodeficiency virus (SIV) SIVmac251 were engineered so that both genes were cotranscribed from a synthetic operon. The expression cassette was cloned into a multicopy-replicating vector, and the expression levels of both nef and gag in the bivalent rBCG(nef-gag) strain were found to be comparable to those of monovalent rBCG(nef) or rBCG(gag) strains. However, extrachromosomal cloning of the nef-gag operon into a replicative plasmid resulted in strains of low genetic stability that rapidly lost the plasmid in vivo. Thus, the nef-gag operon was inserted site specifically into the BCG chromosome by means of mycobacteriophage Ms6-derived vectors. The resulting integrative rBCG(nef-gag) strains showed very high genetic stability both in vitro and in vivo. The in vivo expression of the heterologous genes was much longer lived when the expression cassette was inserted into the BCG chromosome. In one of the strains obtained, integrative cloning did not reduce the expression levels of the genes even though a single copy was present. Accordingly, this strain induced cellular immune responses of the same magnitude as that of the replicative rBCG strain containing several copies of the genes.
Subject(s)
Antigens, Viral/genetics , DNA, Viral , Gene Products, gag/genetics , Gene Products, nef/genetics , Genetic Vectors/genetics , Mycobacterium bovis/genetics , Plasmids , Simian Immunodeficiency Virus/genetics , Animals , Antibodies, Viral/immunology , Antigens, Viral/immunology , Bacteriophages , Cells, Cultured , Chromosomes, Bacterial , Cloning, Molecular/methods , Female , Gene Expression , Gene Products, gag/immunology , Gene Products, nef/immunology , Macrophages/cytology , Macrophages/immunology , Mice , Mice, Inbred BALB C , Mutagenesis, Insertional/methods , Mutagenesis, Site-Directed , Mycobacterium bovis/virology , Operon , Simian Immunodeficiency Virus/immunology , T-Lymphocytes/immunologySubject(s)
Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/physiology , Tuberculosis/microbiology , Tuberculosis/therapy , BCG Vaccine , Cell Wall/physiology , Cholesterol/metabolism , Disease Susceptibility , Drug Resistance, Bacterial/genetics , Genome, Bacterial , Humans , Interferon-gamma/biosynthesis , Mycobacterium tuberculosis/cytology , Mycobacterium tuberculosis/immunology , Phagocytosis , Tuberculosis/epidemiology , Tuberculosis/prevention & controlABSTRACT
Two-component regulatory proteins function in bacteria as sensory and adaptive factors in response to a wide range of environmental stimuli. Some two-component systems, such as PhoP/PhoQ, control transcription of key virulence genes essential for survival in host cells in diverse intracellular bacterial pathogens, including Salmonella sp., Shigella sp. and Yersinia sp. In this study, we have disrupted the phoP gene from Mycobacterium tuberculosis, which codes for a putative transcription regulator factor of the two-component system PhoP/PhoR. The phoP mutant strain exhibited impaired multiplication when cultured in mouse bone marrow-derived macrophages. However, the mutation did not appear to affect survival of the organisms adversely inside macrophages. The mutant strain was also attenuated in vivo in a mouse infection model, with impaired growth observed in the lungs, livers and spleens. The results suggest that the phoP gene is required for intracellular growth of M. tuberculosis but is not essential for persistence of the bacilli.